Genuity Capital Markets
http://www.genuitycm.com/Genuity Capital Markets is a financial services firm providing investment banking, institutional sales and trading, and equity research to its corporate clients. The firm uses a simple Buy, Hold and Sell rating system in its research analysis.
View Older Stories View More Recent Stories
-
Canaccord Genuity Maintains a 'Hold' on Veeco Instruments (VECO); Updating Estimates Post Third Cycle Revision
-
Canaccord Genuity Downgrades Aixtron (AIXG) to Sell; Increasing Risk Combined with Rich Valuation
-
Canaccord Genuity Maintains a 'Buy' on Rovi Corp. (ROVI); Strong Qtr, Outlook Solid; Potential Japan Impact Less Than Anticipated
-
Canaccord Genuity Maintains a 'Buy' on Pegasystems (PEGA); Strong Start to Year; Fundamentals Solid
-
Canaccord Genuity Reiterates a 'Buy' on Nuance Communications (NUAN); Just What the Doctor Ordered: A No-Drama Quarter
-
Canaccord Genuity Reiterates a 'Buy' on Northern Oil and Gas (NOG); Reiterating Oversold Thesis
-
Canaccord Genuity Reiterates a 'Buy' on Voyager Oil & Gas (VOG); Reaffirms 2011 Guidance
-
Canaccord Genuity Reiterates a 'Hold' on GMX Resources (GMXR); Preparing for Rockies Debut
-
Canaccord Genuity Reiterates a 'Sell' on EQT Corp. (EQT); Material Consensus Value Overstatement on Midstream Transfer Price Confusion
-
Canaccord Genuity Maintains a 'Buy' on Carrizo Oil & Gas (CRZO); Q1/11 Largely In Line
-
Canaccord Genuity Reiterates a 'Buy' on Northgate Minerals (NXG); Q1/11 Beats Expectations; Kemess South Ends on Fine Note
-
UPDATE - Canaccord Genuity Upgraded Acuity Brands (AYI) to Buy; Opportunity Warrants Continued Valuation Premium
-
Canaccord Genuity Upgrades Acuity Brands (AYI) to Buy
-
Canaccord Genuity Maintains a 'Buy' on Inhibitex (INHX); Q1/11: Readying for INX-189 Phase II Trials
-
Canaccord Genuity Reiterates a 'Buy' on GenMark Diagnostics (GNMK); XT-8 Placements Lead Again
-
Canaccord Genuity Maintains a 'Hold' on Gen-Probe (GPRO); Reports HPV Data
-
Canaccord Genuity Maintains a 'Hold' on Exelixis (EXEL); Q1 Update; Clarity on Cabo Filing Strategy Soon
-
Canaccord Genuity maintains a 'Hold' on Edwards Lifesciences (EW); Cohort A Stroke Sub-Study Shows TA Equals Higher Stroke Risk
-
Canaccord Genuity Maintains a 'Buy' on ZIOPHARM Oncology (ZIOP); Model Updates Following Q1/11 Results
-
Canaccord Genuity Maintains a 'Buy' on Vical (VICL); Q1/11 Update: Pipeline Programs Move Forward
-
Canaccord Genuity Maintains a 'Buy' on Synta Pharma (SNTA); Q1/11: G-pib Development in NSCLC Advances
-
Canaccord Genuity Reiterates a 'Buy' on BioMimetic Therapeutics (BMTI); Financial Results In-Line; The Quiet Before the Panel
-
Canaccord Genuity Reiterates a 'Buy' on Avanir Pharmaceuticals (AVNR); Q2/11: Slow Start to Nuedexta Launch
-
Canaccord Genuity Maintains a 'Buy' on Valeant Pharmaceuticals (VRX); Q1 Results: Delivering on Synergies
-
Canaccord Genuity Reiterates a 'Buy' on Insulet Corporation (PODD); No Surprises: Q1 Results In-Line and Gen2 Pod Submission on Time
-
Canaccord Genuity Maintains a 'Buy' on Headwaters (HW); Q2 is Rough, Optionality Hangs Tough
-
Canaccord Genuity Maintains a 'Buy' on TechTarget (TTGT); Q1 Revenues Delayed to Q2
-
Canaccord Genuity Reiterates a 'Buy' on Integrated Device Technology (IDTI); In-line Guidance Despite Japan
-
Canaccord Genuity Maintains a 'Buy' on Magnum Hunter (MHR); Reiterating Our Attractively Priced Growth Thesis
-
Canaccord Genuity maintains a 'Buy' on Rosetta Resources (ROSE); Q1/11: Eagle Ford Drives Strong Production Uplift
-
Canaccord Genuity Reiterates a 'Buy' on Abraxas Petroleum (AXAS); Transformational Catalysts Are In Sight
-
UPDATE - Canaccord Genuity downgraded Universal Display (PANL) to Hold on fair Valuation; Long-Term Opportunities Remain
-
Canaccord Genuity Downgrades Universal Display (PANL) to Hold
-
Canaccord Genuity Reiterates a 'Buy' on CF Industries (CF); Relief!!! Hints of Better Things to Come
-
Canaccord Genuity Reiterates a 'Hold' on Celgene (CELG); Revlimid Risks Linger
-
Canaccord Genuity Reiterates a 'Hold' on XOMA, Ltd. (XOMA); Q1/11: Phase 3 Behcet's Q4/11, Phase 2 Cardiovascular 2012
-
Canaccord Genuity Maintains a 'Buy' on Onyx Pharmaceuticals (ONXX); Improved C-Mib Outlook
-
Canaccord Genuity Maintains a 'Buy' on Metalico (MEA); Revving Up for Growth, Designating as a Best Idea
-
Canaccord Genuity Maintains a 'Hold' on Fuel-Tech (FTEK); Q1 Preview: Awaiting Air Pollution Control Catalysts
-
Canaccord Genuity Reiterates a 'Buy' on Elster Group SE (ELT); Get It While The Gas is Getting Good
-
Canaccord Genuity Maintains a 'Buy' on Apple (AAPL); Solid Checks; Ramping iOS Base Drives L-T Earnings
-
Canaccord Genuity Maintains a 'Hold' on Research In Motion (RIMM); Slowing Global Sales: BB OS 7.0 Unlikely to Stem Consumer Share Losses
-
Canaccord Genuity Reiterates a 'Hold' on Gastar Exploration (GST); Expecting Catalyst-Filled H2/11
-
Canaccord Genuity Maintains a 'Hold' on SandRidge Energy (SD); Q1/11 Miss on Lower Production and Weaker Price Realizations
-
Canaccord Genuity Reiterates a 'Buy' on Cimarex Energy (XEC); Looking Past Near-Term Weakness; Remain Permian Bulls
-
Canaccord Genuity Upgrades Ultra Petroleum (UPL) to Hold; Strong Marcellus Results, Likely 2012/13 Guidance Increase
-
Canaccord Genuity Upgrades Continental Resources (CLR) to Buy; on Valuation, Bakken Execution/Extension
-
Canaccord Genuity Maintains a 'Buy' on Thompson Creek Metals (TC); Q1/11 Results Beat Consensus, But Mt. Milligan Capex Goes Up
-
Canaccord Genuity Reiterates a 'Buy' on Vale S.A. (VALE); Q1/11 Results a Slight Miss
-
Canaccord Genuity Maintains a 'Hold' on Cameco Corp (CCJ); Q1/11 Results Below Expectations;
